gadofluorine m profile

gadofluorine M: a protein avid contrast agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	24772582
MeSH ID	M0507667

Synonym
gadofluorine m
2-[4,10-bis(carboxymethyl)-7-[1-[[2-[[(5s)-6-[4-(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctylsulfonyl)piperazin-1-yl]-6-oxo-5-[[2-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyacetyl]amino]hexyl]amino]-2-oxoethyl]amino]-1-oxop

Excerpt	Reference	Relevance
"Gadofluorine M is a gadolinium-containing macrocyclic contrast agent containing hydrophilic and hydrophobic moieties."	( Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with Gadofluorine M. Fayad, ZA; Licha, K; Meding, J; Misselwitz, B; Reinhardt, M; Urich, M; Weinmann, HJ, )	1.07

Excerpt	Reference	Relevance
"Gadofluorine M has been reported to enhance early atherosclerotic plaque signals in magnetic resonance imaging (MRI). "	( Targeted contrast agent helps to monitor advanced plaque during progression: a magnetic resonance imaging study in rabbits. Abendschein, D; El Naqa, I; Misselwitz, B; Ochoa, E; Woodard, PK; Yang, D; Zheng, J, 2008)	1.79

Excerpt	Reference	Relevance
"Gadofluorine M displays a high r(1) relaxivity and is spontaneously phagocytosed by macrophages."	( Cell labeling with the positive MR contrast agent Gadofluorine M. Bauer, JS; Boddington, S; Daldrup-Link, HE; Fu, Y; Golovko, D; Henning, TD; McDonald, DM; Meier, R; Pietsch, H; Saborowski, O; Sennino, B, 2007)	1.31

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	15 (57.69)	29.6817
2010's	11 (42.31)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	28 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	2.03	1	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
gadolinium Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.	7.46	2	f-block element atom; lanthanoid atom
lysophosphatidylcholines lysophosphatidylcholine : An acylglycerophosphocholine resulting from partial hydrolysis of a phosphatidylcholine, which removes one of the fatty acyl groups. The structure is depicted in the image where R1 = acyl, R2 = H or where R1 = H, R2 = acyl.	2.03	1	1-O-acyl-sn-glycero-3-phosphocholine
carbocyanines Carbocyanines: Compounds that contain three methine groups. They are frequently used as cationic dyes used for differential staining of biological materials.	2.45	2	cyanine dye; organic iodide salt	fluorochrome
gadolinium dtpa Gadolinium DTPA: A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)	3.84	11	gadolinium coordination entity	MRI contrast agent
cyanine dye 3 cyanine dye 3: structures of Cy3 derivatives given in first source	2.45	2

Condition	Relationship Strength	Studies
Canine Diseases [description not available]	2.07	1
Cancer of Head [description not available]	2.07	1
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.07	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.66	9
Allergic Encephalomyelitis [description not available]	2.74	3
MS (Multiple Sclerosis) [description not available]	2.44	2
Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)	2.44	2
Blood Clot [description not available]	2.05	1
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	7.05	1
Muscular Dystrophy, Animal MUSCULAR DYSTROPHY that occurs in VERTEBRATE animals.	2.45	2
Extravasation of Contrast Media [description not available]	2.05	1
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2.05	1
Disease Exacerbation [description not available]	2.45	2
Becker Muscular Dystrophy [description not available]	2.05	1
Limb-Girdle Muscular Dystrophies [description not available]	2.05	1
Muscular Dystrophy [description not available]	2.05	1
Muscular Dystrophies A heterogeneous group of inherited MYOPATHIES, characterized by wasting and weakness of the SKELETAL MUSCLE. They are categorized by the sites of MUSCLE WEAKNESS; AGE OF ONSET; and INHERITANCE PATTERNS.	2.05	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	3.45	7
Muscular Dystrophy, Duchenne An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)	2.05	1
Muscular Dystrophies, Limb-Girdle A heterogenous group of inherited muscular dystrophy that can be autosomal dominant or autosomal recessive. There are many forms (called LGMDs) involving genes encoding muscle membrane proteins such as the sarcoglycan (SARCOGLYCANS) complex that interacts with DYSTROPHIN. The disease is characterized by progressing wasting and weakness of the proximal muscles of arms and legs around the HIPS and SHOULDERS (the pelvic and shoulder girdles).	2.05	1
Cardiovascular Stroke [description not available]	2.45	2
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	2.45	2
Atherogenesis [description not available]	2.74	3
Aortic Aneurysm, Ruptured [description not available]	2.05	1
Aortic Diseases Pathological processes involving any part of the AORTA.	2.45	2
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	2.74	3
Innate Inflammatory Response [description not available]	2.74	3
Angiogenesis, Pathologic [description not available]	2.05	1
Rupture Forcible or traumatic tear or break of an organ or other soft part of the body.	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	7.74	3
Lymph Node Metastasis [description not available]	2.76	3
Experimental Neoplasms [description not available]	2.48	2
Benign Neoplasms, Brain [description not available]	2.46	2
Glial Cell Tumors [description not available]	2.46	2
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.46	2
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.46	2
Cancer of Rectum [description not available]	2.07	1
Rectal Neoplasms Tumors or cancer of the RECTUM.	2.07	1
Cancer of Stomach [description not available]	2.07	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.07	1
Clinically Isolated CNS Demyelinating Syndrome [description not available]	2.03	1
Peripheral Nerve Diseases [description not available]	2.03	1
Demyelinating Diseases Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.	2.03	1
Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.	2.03	1
Chronic Illness [description not available]	2.04	1
Acute Disease Disease having a short and relatively severe course.	2.04	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.04	1

gadofluorine m

Description

Cross-References

Synonyms (2)

Research Excerpts

Overview

Effects

Actions

Research

Studies (26)

Market Indicators

Research Demand Index: 11.01

Study Types

gadofluorine m

Description

Cross-References

Synonyms (2)

Research Excerpts

Overview

Effects

Actions

Research

Studies (26)

Market Indicators

Research Demand Index: 11.01

Study Types

Related Drugs (6)

Related Conditions (47)